{"protocolSection":{"identificationModule":{"nctId":"NCT03334617","orgStudyIdInfo":{"id":"D6185C00001"},"secondaryIdInfos":[{"id":"138050","type":"REGISTRY","domain":"IND"},{"id":"2023-509004-15-00","type":"OTHER","domain":"EU CT number"},{"id":"2017-002208-28","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","officialTitle":"An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).","acronym":"HUDSON"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-12-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-09-13","type":"ACTUAL"},"completionDateStruct":{"date":"2026-09-11","type":"ESTIMATED"},"studyFirstSubmitDate":"2017-09-22","studyFirstSubmitQcDate":"2017-11-03","studyFirstPostDateStruct":{"date":"2017-11-07","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-08-27","resultsFirstSubmitQcDate":"2025-10-10","resultsFirstPostDateStruct":{"date":"2025-10-27","type":"ESTIMATED"},"lastUpdateSubmitDate":"2025-10-10","lastUpdatePostDateStruct":{"date":"2025-10-27","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.","detailedDescription":"This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic non-small cell lung cancer (NSCLC) who have progressed on an anti-programmed cell death-1/anti-programmed cell death ligand 1 (anti-PD-1/PD-L1) containing therapy. This study is modular in design, consisting of a number of treatment cohorts, allowing evaluation of the efficacy, safety, and tolerability of multiple treatment arms. There is currently no established therapy for participants who have received immune checkpoint inhibitors and platinum-doublet therapies, and novel treatments are urgently needed.\n\nThis protocol has a modular design, with the potential for future treatment arms to be added via protocol amendment."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"],"keywords":["Non-small cell lung cancer","NSCLC","anti-PD-1/PD-L1","umbrella study","Durvalumab","MEDI4736","Olaparib","AZD2281","AZD9150","AZD6738","Vistusertib","AZD2014","Oleclumab","MEDI9447","Trastuzumab deruxtecan","DS-8201a","cediranib","AZD2171"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.\n\nWithin each module, there will be treatment cohorts.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":528,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","type":"EXPERIMENTAL","description":"Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) will receive IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed.","interventionNames":["Drug: Durvalumab","Drug: Olaparib"]},{"label":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","type":"EXPERIMENTAL","description":"Participants with detectable aberrations in liver kinase B1 (LKB1) will receive IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed.","interventionNames":["Drug: Durvalumab","Drug: Olaparib"]},{"label":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","type":"EXPERIMENTAL","description":"Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) will receive IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed.","interventionNames":["Drug: Durvalumab","Drug: Olaparib"]},{"label":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","type":"EXPERIMENTAL","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) will receive IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed.","interventionNames":["Drug: Durvalumab","Drug: Olaparib"]},{"label":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","type":"EXPERIMENTAL","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) will receive IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants will receive AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Danvatirsen"]},{"label":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","type":"EXPERIMENTAL","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) will receive IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants will receive AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Danvatirsen"]},{"label":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","type":"EXPERIMENTAL","description":"Participants who are ataxia telangiectasia mutated (ATM)-deficiecy will receive oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants will receive IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Ceralasertib"]},{"label":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","type":"EXPERIMENTAL","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) will receive oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants will receive IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Ceralasertib"]},{"label":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","type":"EXPERIMENTAL","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) will receive oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants will receive IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Ceralasertib"]},{"label":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","type":"EXPERIMENTAL","description":"Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) will receive IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Vistusertib"]},{"label":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","type":"EXPERIMENTAL","description":"Participants with high expression of cluster of differentiation 73 (CD73) will receive IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Oleclumab"]},{"label":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","type":"EXPERIMENTAL","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) will receive IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Oleclumab"]},{"label":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","type":"EXPERIMENTAL","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) will receive IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Oleclumab"]},{"label":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab deruxtecan 5.4mg/kg","type":"EXPERIMENTAL","description":"Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations will receive IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Trastuzumab deruxtecan"]},{"label":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab deruxtecan 5.4mg/kg","type":"EXPERIMENTAL","description":"Participants whose tumours harbour selected HER2 mutations will receive IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Trastuzumab deruxtecan"]},{"label":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","type":"EXPERIMENTAL","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) will receive IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Cediranib"]},{"label":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","type":"EXPERIMENTAL","description":"Participants who are ATM-deficient or with detectable aberrations in the ATM gene will receive oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","interventionNames":["Drug: Ceralasertib"]},{"label":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","type":"EXPERIMENTAL","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) will receive IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Ceralasertib"]},{"label":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","type":"EXPERIMENTAL","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) will receive IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Ceralasertib"]},{"label":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","type":"EXPERIMENTAL","description":"Participants, independent of their molecular aberration status, will receive oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants will receive IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Ceralasertib"]},{"label":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","type":"EXPERIMENTAL","description":"Participants, independent of their molecular aberration status, will receive oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants will receive IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.","interventionNames":["Drug: Durvalumab","Drug: Ceralasertib"]},{"label":"Module 11 Cohort C.11.240: AZD6738 240 mg","type":"EXPERIMENTAL","description":"Participants, independent of their molecular aberration status, will receive oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.","interventionNames":["Drug: Ceralasertib"]}],"interventions":[{"type":"DRUG","name":"Durvalumab","description":"Participants will receive IV infusion of durvalumab as stated in arm description.","armGroupLabels":["Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab deruxtecan 5.4mg/kg","Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab deruxtecan 5.4mg/kg","Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg"]},{"type":"DRUG","name":"Danvatirsen","description":"Participants will receive IV infusion of danvatirsen as stated in arm description.","armGroupLabels":["Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg"],"otherNames":["AZD9150"]},{"type":"DRUG","name":"Ceralasertib","description":"Participants will receive oral tablet of ceralasertib as stated in arm description.","armGroupLabels":["Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","Module 11 Cohort C.11.240: AZD6738 240 mg","Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg"],"otherNames":["AZD6738"]},{"type":"DRUG","name":"Vistusertib","description":"Participants will receive oral tablets of vistusertib as stated in arm description.","armGroupLabels":["Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg"]},{"type":"DRUG","name":"Olaparib","description":"Participants will receive oral tablets of olaparib as stated in arm description.","armGroupLabels":["Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg"]},{"type":"DRUG","name":"Oleclumab","description":"Participants will receive IV infusion of oleclumab as stated in arm description.","armGroupLabels":["Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg"]},{"type":"DRUG","name":"Trastuzumab deruxtecan","description":"Participants will receive IV infusion of trastuzumab deruxtecan as stated in arm description.","armGroupLabels":["Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab deruxtecan 5.4mg/kg","Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab deruxtecan 5.4mg/kg"],"otherNames":["T-DXd"]},{"type":"DRUG","name":"Cediranib","description":"Participants will receive oral tablets of cediranib as stated in arm description.","armGroupLabels":["Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg"],"otherNames":["AZD2171"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)","description":"Objective response was defined as participants with a confirmed investigator-assessed response complete response (CR) or partial response (PR) based on RECIST v 1.1. The CR is defined as disappearance of all target (TL) and non-target lesions (NTL), and any pathological lymph node (whether target or nontarget) must have reduction in short axis to \\<10 mm. The PR is defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum diameters, as long as criteria for progressive disease (PD) are not met. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. Percentage of participants with objective response was reported.","timeFrame":"Baseline (<=28 days before treatment), then every 6 weeks for 24 weeks from Cycle 1 Day 1, then every 8 weeks (every 9 weeks in Module 6) until disease progression or 90 days after study drug discontinuation (approximately 2 years)"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"The OS is defined as the time from the first dose of any study drug until death due to any cause regardless of whether the participant withdraws from study treatment or receives subsequent cancer therapy. The overall survival was analyzed using the Kaplan-Meier method.","timeFrame":"Every 3 months after safety follow-up visit (90 days after study drug discontinuation) until planned database lock for a module (either 12 months after last participant has started treatment or when 75% of participants died) (approximately up to 2 years)"},{"measure":"Progression-Free Survival (PFS) Per RECIST v1.1","description":"The PFS is defined as time from first dose of any study drug until date of objective disease progression (PD) per RECIST v1.1 or death by any cause, regardless of whether the participant withdraws from study therapy or receives another anti-cancer therapy prior to progression. The PD is defined as a \\>= 20% increase in the sum of diameters of TLs and an absolute increase of \\>= 5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters, or unequivocal progression of existing NTL. The PFS was analyzed using the Kaplan-Meier method","timeFrame":"Every 3 months after safety follow-up visit (90 days after study drug discontinuation) until planned database lock for a module (either 12 months after last participant has started treatment or when 75% of participants died) (approximately up to 2 years)"},{"measure":"Best Percentage Change From Baseline in Tumour Size","description":"The best percentage change in tumour size from baseline i.e. the maximum reduction from baseline or the minimum increase from baseline in absence of a reduction from baseline based on all post baseline assessments is reported. Tumour size is sum of the longest diameters (or short axis measurements for lymph nodes) of the target lesions. Baseline was defined as last evaluable assessment prior to starting treatment. The percentage change in target lesion tumour size at each week X for which data are available was obtained for each participant taking the difference between the sum of the target lesions at each week X and the sum of the target lesions at baseline divided by the sum of the target lesions at baseline multiplied by 100 (i.e. \\[week X - baseline\\]/baseline \\* 100).","timeFrame":"Baseline (<=28 days prior to starting treatment) then every 6 weeks for first 24 weeks relative to the date of first dose/combination therapy (Cycle 1 Day 1), then every 8 weeks (except Module 6)/9 weeks (Module 6) thereafter (approximately up to 2 years)"},{"measure":"Percentage of Participants With Disease Control (DC) Per RECIST v1.1","description":"Module (M) 1, 4, 5, 6, 7, 8, 9, 11: DCR at 12 and 24 weeks is defined as percentage of participants who have best overall response (BoR) of CR or PR in first 13/25 weeks, respectively, post start of any study drug or with duration of SD for at least 11/23 weeks, respectively, after start of any study drug. M2, M3, M10: DCR at 12 and 24 weeks is defined as percentage of participants who have BoR of CR or PR within first 100 days (M2, M3, M10) or 184 days (M2, M3, M10) after start of any study drug, or have SD lasting at least 86 days (M2)/82 days (M3, M10), respectively, or 170 days (M2)/166 days (M3, M10), respectively, post start of any study drug. CR is defined as disappearance of all TL and NTLs, and any pathological lymph node (whether target or nontarget) must have reduction in short axis to \\<10 mm. PR is defined as at least 30% decrease in sum of diameters of TLs, taking as reference baseline sum diameters, as long as criteria for PD are not met.","timeFrame":"At 12 and 24 weeks after the start of study drug"},{"measure":"Duration of Response (DoR) Per RECIST v1.1","description":"The DoR is defined as the time from the first documented confirmed response (CR or PR) until the first documented PD or death in the absence of disease progression. The CR is defined as disappearance of all TLs and NTLs, and any pathological lymph node (whether target or nontarget) must have reduction in short axis to \\<10 mm. The PR is defined as at least a 30 decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters, as long as criteria for PD are not met. The PD is defined as a \\>=20% increase in the sum of diameters of TLs and an absolute increase of \\>=5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters, or unequivocal progression of existing NTL. The DoR was analyzed using the Kaplan-Meier method.","timeFrame":"Baseline (<=28 days before treatment), then every 6 weeks for 24 weeks from Cycle 1 Day 1, then every 8 weeks (every 9 weeks in Module 6) until disease progression or 90 days after study drug discontinuation (approximately 2 years)"},{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)","description":"An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.","timeFrame":"Day 1 thorugh 58.6 months (maximum observed duration)"},{"measure":"Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs","description":"Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. Abnormal clinical laboratory parameters defined as any abnormal finding during analysis of hematology, clinical chemistry, and urinalysis.","timeFrame":"Day 1 thorugh 58.6 months (maximum observed duration)"},{"measure":"Number of Participants With Abnormal Vital Signs Reported as TEAEs","description":"Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (blood pressure, pulse rate, temperature, and respiration rate).","timeFrame":"Day 1 thorugh 58.6 months (maximum observed duration)"},{"measure":"Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs","description":"Number of participants with abnormal physical examination findings reported as TEAEs are reported. Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the pre-dose assessment was reported as an AE.","timeFrame":"Day 1 thorugh 58.6 months (maximum observed duration)"},{"measure":"Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs","description":"Number of participants with abnormal ECGs reported as TEAEs are reported.","timeFrame":"Day 1 thorugh 58.6 months (maximum observed duration)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* At least 18 years of age at the time of signing the informed consent form.\n* Participant must have histologically or cytologically confirmed metastatic or locally advanced and recurrent non-small-cell lung cancer (NSCLC) which is progressing.\n* Participants eligible for second- or later-line therapy, who must have received an anti-programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) containing therapy and a platinum-doublet regimen for locally advanced or metastatic NSCLC either separately or in combination. Prior durvalumab is acceptable. The participant must have had disease progression on a prior line of anti-PD-1/PD-L1 therapy.\n* Eastern Cooperative Oncology Group/World Health Organization (ECOG/WHO) performance status of 0 to 1, and a minimum life expectancy of 12 weeks.\n* Participant must have at least 1 lesion that can be accurately measured. A previously irradiated lesion can be considered a target lesion if the lesion has clearly progressed.\n* Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal participants.\n\nExclusion Criteria:\n\n* Participants whose tumour samples have targetable alterations in epidermal growth factor receptor (EGFR) and/or anaplastic lymphoma kinase (ALK) at initial diagnosis are excluded. In addition, participants whose tumour samples are known to have targetable alterations in ROS1, BRAF, MET or RET, are to be excluded.\n* Active or prior documented autoimmune or inflammatory disorders.\n* Active infection including tuberculosis, hepatitis B (known positive hepatitis B virus \\[HBV\\] surface antigen \\[HBsAg\\] result), hepatitis C, or human immunodeficiency virus (positive human immunodeficiency virus \\[HIV\\] 1/2 antibodies).\n* Female participant who are pregnant or breastfeeding, or male or female participants of reproductive potential who are not willing to employ effective birth control.\n* Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients, or history of severe hypersensitivity reactions to other monoclonal antibodies.\n* Participant has spinal cord compression or symptomatic brain metastases.\n* Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Participants may receive treatment with bisphosphonates or receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitors for the treatment of bone metastases.\n* History of active primary immunodeficiency.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"John Heymach, M.D, Ph.D","affiliation":"The University of Texas MD Anderson Cancer Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Research Site","city":"Duarte","state":"California","zip":"91010","country":"United States","geoPoint":{"lat":34.13945,"lon":-117.97729}},{"facility":"Research Site","city":"Fullerton","state":"California","zip":"92835","country":"United States","geoPoint":{"lat":33.87029,"lon":-117.92534}},{"facility":"Research Site","city":"La Jolla","state":"California","zip":"92093","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Research Site","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Research Site","city":"Washington D.C.","state":"District of Columbia","zip":"20016","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Research Site","city":"Chicago","state":"Illinois","zip":"60637","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Research Site","city":"Baltimore","state":"Maryland","zip":"21224","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Research Site","city":"Baltimore","state":"Maryland","zip":"21287","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Research Site","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Research Site","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Research Site","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Research Site","city":"Philadelphia","state":"Pennsylvania","zip":"19111","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Research Site","city":"Pittsburgh","state":"Pennsylvania","zip":"15232","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Research Site","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Research Site","city":"Nashville","state":"Tennessee","zip":"37212","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Research Site","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Research Site","city":"Fairfax","state":"Virginia","zip":"22031","country":"United States","geoPoint":{"lat":38.84622,"lon":-77.30637}},{"facility":"Research Site","city":"Innsbruck","zip":"6020","country":"Austria","geoPoint":{"lat":47.26266,"lon":11.39454}},{"facility":"Research Site","city":"Salzburg","zip":"5020","country":"Austria","geoPoint":{"lat":47.79941,"lon":13.04399}},{"facility":"Research Site","city":"Vienna","zip":"1140","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Research Site","city":"Vienna","zip":"1210","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Research Site","city":"Edmonton","state":"Alberta","zip":"T6G 1Z2","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Research Site","city":"Brampton","state":"Ontario","zip":"L6R 3J7","country":"Canada","geoPoint":{"lat":43.68341,"lon":-79.76633}},{"facility":"Research Site","city":"Ottawa","state":"Ontario","zip":"K1H 8L6","country":"Canada","geoPoint":{"lat":45.41117,"lon":-75.69812}},{"facility":"Research Site","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Research Site","city":"Montreal","state":"Quebec","zip":"H2X 3E4","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Research Site","city":"Bordeaux","zip":"33076","country":"France","geoPoint":{"lat":44.84124,"lon":-0.58046}},{"facility":"Research Site","city":"Nantes","zip":"44093","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"Research Site","city":"Paris","zip":"75877","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Research Site","city":"Villejuif","zip":"94800","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}},{"facility":"Research Site","city":"Berlin","zip":"12203","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Research Site","city":"Esslingen a.N.","zip":"73730","country":"Germany"},{"facility":"Research Site","city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Research Site","city":"Heidelberg","zip":"69126","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Research Site","city":"Haifa","zip":"31096","country":"Israel","geoPoint":{"lat":32.81303,"lon":34.99928}},{"facility":"Research Site","city":"Kfar Saba","zip":"95847","country":"Israel","geoPoint":{"lat":32.175,"lon":34.90694}},{"facility":"Research Site","city":"Petah Tikva","zip":"49100","country":"Israel","geoPoint":{"lat":32.08707,"lon":34.88747}},{"facility":"Research Site","city":"Ramat Gan","zip":"5265601","country":"Israel","geoPoint":{"lat":32.08227,"lon":34.81065}},{"facility":"Research Site","city":"Seoul","zip":"03080","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Seoul","zip":"6351","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Madrid","zip":"28007","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Madrid","zip":"28034","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Seville","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}}]},"referencesModule":{"references":[{"pmid":"38351187","type":"DERIVED","citation":"Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, Awad MM, Thomas M, Goss G, Wheatley-Price P, Shepherd FA, Florescu M, Cheema P, Chu QSC, Kim SW, Morgensztern D, Johnson ML, Cousin S, Kim DW, Moskovitz MT, Vicente D, Aronson B, Hobson R, Ambrose HJ, Khosla S, Reddy A, Russell DL, Keddar MR, Conway JP, Barrett JC, Dean E, Kumar R, Dressman M, Jewsbury PJ, Iyer S, Barry ST, Cosaert J, Heymach JV. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat Med. 2024 Mar;30(3):716-729. doi: 10.1038/s41591-024-02808-y. Epub 2024 Feb 13."}],"seeAlsoLinks":[{"label":"Redacted SAP","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D6185C00001&amp;attachmentIdentifier=73155d56-c95a-483f-9c56-630afd5df1e8&amp;fileName=D6185c00001-SAP-v9.0_15Feb24.pdf&amp;versionIdentifier="},{"label":"Redacted CSP","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D6185C00001&amp;attachmentIdentifier=7d0cabb4-4573-443e-ab4f-1f9f777874f2&amp;fileName=d6185c00001-csp-v14_Redacted.pdf&amp;versionIdentifier="},{"label":"Redacted CSR synopsis","url":"https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D6185C00001&amp;attachmentIdentifier=35106804-b43c-4872-b55a-63b9b4465ba2&amp;fileName=CSR_Synopsis_(Modules_1-11)_Redacted_PDF-A.pdf&amp;versionIdentifier="}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.\n\nYes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.","infoTypes":["STUDY_PROTOCOL","SAP"],"timeFrame":"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","accessCriteria":"When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","url":"https://astrazenecagroup-dt.pharmacm.com/DT/Home"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 529 participants were enrolled in this study.","recruitmentDetails":"The study was conducted at 45 centers in 8 countries (Austria, Canada, France, Germany, Israel, South Korea, Spain, and the United States).","groups":[{"id":"FG000","title":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) received IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed."},{"id":"FG001","title":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations in liver kinase B1 (LKB1) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"FG002","title":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"FG003","title":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"FG004","title":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"FG005","title":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"FG006","title":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who are ataxia telangiectasia mutated (ATM)-deficiecy received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"FG007","title":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"FG008","title":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"FG009","title":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","description":"Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) received IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"FG010","title":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants with high expression of cluster of differentiation 73 (CD73) received IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"FG011","title":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"FG012","title":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"FG013","title":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations received IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"FG014","title":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours harbour selected HER2 mutations received IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"FG015","title":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"FG016","title":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","description":"Participants who are ATM-deficient or with detectable aberrations in the ATM gene received oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"FG017","title":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"FG018","title":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"FG019","title":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"FG020","title":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"FG021","title":"Module 11 Cohort C.11.240: AZD6738 240 mg","description":"Participants, independent of their molecular aberration status, received oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"22"},{"groupId":"FG003","numSubjects":"23"},{"groupId":"FG004","numSubjects":"23"},{"groupId":"FG005","numSubjects":"22"},{"groupId":"FG006","numSubjects":"31"},{"groupId":"FG007","numSubjects":"38"},{"groupId":"FG008","numSubjects":"58"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"23"},{"groupId":"FG011","numSubjects":"9"},{"groupId":"FG012","numSubjects":"25"},{"groupId":"FG013","numSubjects":"23"},{"groupId":"FG014","numSubjects":"20"},{"groupId":"FG015","numSubjects":"22"},{"groupId":"FG016","numSubjects":"15"},{"groupId":"FG017","numSubjects":"19"},{"groupId":"FG018","numSubjects":"24"},{"groupId":"FG019","numSubjects":"34"},{"groupId":"FG020","numSubjects":"17"},{"groupId":"FG021","numSubjects":"38"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"1"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"2"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"20"},{"groupId":"FG003","numSubjects":"23"},{"groupId":"FG004","numSubjects":"22"},{"groupId":"FG005","numSubjects":"20"},{"groupId":"FG006","numSubjects":"31"},{"groupId":"FG007","numSubjects":"38"},{"groupId":"FG008","numSubjects":"57"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"23"},{"groupId":"FG011","numSubjects":"8"},{"groupId":"FG012","numSubjects":"25"},{"groupId":"FG013","numSubjects":"23"},{"groupId":"FG014","numSubjects":"20"},{"groupId":"FG015","numSubjects":"22"},{"groupId":"FG016","numSubjects":"15"},{"groupId":"FG017","numSubjects":"19"},{"groupId":"FG018","numSubjects":"24"},{"groupId":"FG019","numSubjects":"33"},{"groupId":"FG020","numSubjects":"17"},{"groupId":"FG021","numSubjects":"36"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"20"},{"groupId":"FG003","numSubjects":"21"},{"groupId":"FG004","numSubjects":"20"},{"groupId":"FG005","numSubjects":"16"},{"groupId":"FG006","numSubjects":"28"},{"groupId":"FG007","numSubjects":"35"},{"groupId":"FG008","numSubjects":"47"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"19"},{"groupId":"FG011","numSubjects":"6"},{"groupId":"FG012","numSubjects":"20"},{"groupId":"FG013","numSubjects":"22"},{"groupId":"FG014","numSubjects":"17"},{"groupId":"FG015","numSubjects":"18"},{"groupId":"FG016","numSubjects":"12"},{"groupId":"FG017","numSubjects":"15"},{"groupId":"FG018","numSubjects":"16"},{"groupId":"FG019","numSubjects":"27"},{"groupId":"FG020","numSubjects":"14"},{"groupId":"FG021","numSubjects":"27"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"1"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"1"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"2"},{"groupId":"FG015","numSubjects":"1"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"1"},{"groupId":"FG018","numSubjects":"1"},{"groupId":"FG019","numSubjects":"1"},{"groupId":"FG020","numSubjects":"0"},{"groupId":"FG021","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"8"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"3"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"3"},{"groupId":"FG013","numSubjects":"1"},{"groupId":"FG014","numSubjects":"1"},{"groupId":"FG015","numSubjects":"3"},{"groupId":"FG016","numSubjects":"3"},{"groupId":"FG017","numSubjects":"3"},{"groupId":"FG018","numSubjects":"7"},{"groupId":"FG019","numSubjects":"4"},{"groupId":"FG020","numSubjects":"1"},{"groupId":"FG021","numSubjects":"4"}]},{"type":"Continuing study off treatment at data cut-off","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"1"},{"groupId":"FG020","numSubjects":"2"},{"groupId":"FG021","numSubjects":"4"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Intention to treat (ITT) analysis population included all enrolled participants who received at least 1 dose of the study drug and were analyzed according to their assigned cohort and planned treatment.","groups":[{"id":"BG000","title":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) received IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed."},{"id":"BG001","title":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations in liver kinase B1 (LKB1) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"BG002","title":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"BG003","title":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"BG004","title":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"BG005","title":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"BG006","title":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who are ataxia telangiectasia mutated (ATM)-deficiecy received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"BG007","title":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"BG008","title":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"BG009","title":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","description":"Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) received IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"BG010","title":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants with high expression of cluster of differentiation 73 (CD73) received IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"BG011","title":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"BG012","title":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"BG013","title":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations received IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"BG014","title":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours harbour selected HER2 mutations received IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"BG015","title":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"BG016","title":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","description":"Participants who are ATM-deficient or with detectable aberrations in the ATM gene received oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"BG017","title":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"BG018","title":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"BG019","title":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"BG020","title":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"BG021","title":"Module 11 Cohort C.11.240: AZD6738 240 mg","description":"Participants, independent of their molecular aberration status, received oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"BG022","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"23"},{"groupId":"BG004","value":"23"},{"groupId":"BG005","value":"22"},{"groupId":"BG006","value":"31"},{"groupId":"BG007","value":"38"},{"groupId":"BG008","value":"58"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"23"},{"groupId":"BG011","value":"9"},{"groupId":"BG012","value":"25"},{"groupId":"BG013","value":"23"},{"groupId":"BG014","value":"20"},{"groupId":"BG015","value":"22"},{"groupId":"BG016","value":"15"},{"groupId":"BG017","value":"19"},{"groupId":"BG018","value":"24"},{"groupId":"BG019","value":"34"},{"groupId":"BG020","value":"17"},{"groupId":"BG021","value":"38"},{"groupId":"BG022","value":"529"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59.9","spread":"10.4"},{"groupId":"BG001","value":"60.2","spread":"11.6"},{"groupId":"BG002","value":"60.9","spread":"7.6"},{"groupId":"BG003","value":"66.5","spread":"8.6"},{"groupId":"BG004","value":"63.7","spread":"9.8"},{"groupId":"BG005","value":"64.1","spread":"9.5"},{"groupId":"BG006","value":"61.2","spread":"8.2"},{"groupId":"BG007","value":"62.2","spread":"8.8"},{"groupId":"BG008","value":"62.7","spread":"9.4"},{"groupId":"BG009","value":"NA","spread":"NA","comment":"Mean was not reported due to concern with participant's confidentiality. Standard deviation is not calculated as only one participant is involved in Module 4."},{"groupId":"BG010","value":"60.4","spread":"10.2"},{"groupId":"BG011","value":"61.9","spread":"7.6"},{"groupId":"BG012","value":"66.2","spread":"8.6"},{"groupId":"BG013","value":"62.7","spread":"11.1"},{"groupId":"BG014","value":"61.5","spread":"12.8"},{"groupId":"BG015","value":"65.8","spread":"8.8"},{"groupId":"BG016","value":"66.7","spread":"8.2"},{"groupId":"BG017","value":"61.1","spread":"8.5"},{"groupId":"BG018","value":"67.4","spread":"11.5"},{"groupId":"BG019","value":"62.4","spread":"8.4"},{"groupId":"BG020","value":"64.1","spread":"10.9"},{"groupId":"BG021","value":"62.6","spread":"8.4"},{"groupId":"BG022","value":"63.0","spread":"9.5"}]}]}]},{"title":"Sex/Gender, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Female","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"15"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"17"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"11"},{"groupId":"BG011","value":"7"},{"groupId":"BG012","value":"9"},{"groupId":"BG013","value":"8"},{"groupId":"BG014","value":"11"},{"groupId":"BG015","value":"5"},{"groupId":"BG016","value":"5"},{"groupId":"BG017","value":"5"},{"groupId":"BG018","value":"10"},{"groupId":"BG019","value":"9"},{"groupId":"BG020","value":"4"},{"groupId":"BG021","value":"13"},{"groupId":"BG022","value":"198"}]}]},{"title":"Male","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"16"},{"groupId":"BG007","value":"28"},{"groupId":"BG008","value":"41"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"12"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"16"},{"groupId":"BG013","value":"15"},{"groupId":"BG014","value":"9"},{"groupId":"BG015","value":"17"},{"groupId":"BG016","value":"10"},{"groupId":"BG017","value":"14"},{"groupId":"BG018","value":"14"},{"groupId":"BG019","value":"25"},{"groupId":"BG020","value":"13"},{"groupId":"BG021","value":"25"},{"groupId":"BG022","value":"330"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"1"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"2"},{"groupId":"BG014","value":"1"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"4"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"23"},{"groupId":"BG004","value":"21"},{"groupId":"BG005","value":"22"},{"groupId":"BG006","value":"29"},{"groupId":"BG007","value":"36"},{"groupId":"BG008","value":"55"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"22"},{"groupId":"BG011","value":"9"},{"groupId":"BG012","value":"23"},{"groupId":"BG013","value":"21"},{"groupId":"BG014","value":"19"},{"groupId":"BG015","value":"21"},{"groupId":"BG016","value":"15"},{"groupId":"BG017","value":"19"},{"groupId":"BG018","value":"24"},{"groupId":"BG019","value":"34"},{"groupId":"BG020","value":"17"},{"groupId":"BG021","value":"38"},{"groupId":"BG022","value":"511"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"2"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"1"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"14"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"6"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"7"},{"groupId":"BG013","value":"5"},{"groupId":"BG014","value":"4"},{"groupId":"BG015","value":"3"},{"groupId":"BG016","value":"1"},{"groupId":"BG017","value":"4"},{"groupId":"BG018","value":"4"},{"groupId":"BG019","value":"6"},{"groupId":"BG020","value":"3"},{"groupId":"BG021","value":"5"},{"groupId":"BG022","value":"87"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"2"},{"groupId":"BG015","value":"1"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"12"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"23"},{"groupId":"BG007","value":"15"},{"groupId":"BG008","value":"33"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"15"},{"groupId":"BG011","value":"9"},{"groupId":"BG012","value":"13"},{"groupId":"BG013","value":"15"},{"groupId":"BG014","value":"13"},{"groupId":"BG015","value":"16"},{"groupId":"BG016","value":"12"},{"groupId":"BG017","value":"9"},{"groupId":"BG018","value":"15"},{"groupId":"BG019","value":"21"},{"groupId":"BG020","value":"11"},{"groupId":"BG021","value":"33"},{"groupId":"BG022","value":"340"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"13"},{"groupId":"BG008","value":"16"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"6"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"5"},{"groupId":"BG013","value":"3"},{"groupId":"BG014","value":"1"},{"groupId":"BG015","value":"2"},{"groupId":"BG016","value":"2"},{"groupId":"BG017","value":"6"},{"groupId":"BG018","value":"5"},{"groupId":"BG019","value":"7"},{"groupId":"BG020","value":"3"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"89"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)","description":"Objective response was defined as participants with a confirmed investigator-assessed response complete response (CR) or partial response (PR) based on RECIST v 1.1. The CR is defined as disappearance of all target (TL) and non-target lesions (NTL), and any pathological lymph node (whether target or nontarget) must have reduction in short axis to \\<10 mm. The PR is defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum diameters, as long as criteria for progressive disease (PD) are not met. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. Percentage of participants with objective response was reported.","populationDescription":"Evaluable for response population included all dosed participants who had measurable disease at baseline and who were analyzed according to their assigned cohort and planned treatment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"80% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline (<=28 days before treatment), then every 6 weeks for 24 weeks from Cycle 1 Day 1, then every 8 weeks (every 9 weeks in Module 6) until disease progression or 90 days after study drug discontinuation (approximately 2 years)","groups":[{"id":"OG000","title":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) received IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed."},{"id":"OG001","title":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations in liver kinase B1 (LKB1) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG002","title":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG003","title":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG004","title":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG005","title":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG006","title":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who are ataxia telangiectasia mutated (ATM)-deficiecy received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG007","title":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG008","title":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG009","title":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","description":"Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) received IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG010","title":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants with high expression of cluster of differentiation 73 (CD73) received IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG011","title":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG012","title":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG013","title":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations received IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG014","title":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours harbour selected HER2 mutations received IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG015","title":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG016","title":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","description":"Participants who are ATM-deficient or with detectable aberrations in the ATM gene received oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG017","title":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG018","title":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG019","title":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG020","title":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG021","title":"Module 11 Cohort C.11.240: AZD6738 240 mg","description":"Participants, independent of their molecular aberration status, received oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"31"},{"groupId":"OG007","value":"37"},{"groupId":"OG008","value":"58"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"23"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"25"},{"groupId":"OG013","value":"23"},{"groupId":"OG014","value":"20"},{"groupId":"OG015","value":"22"},{"groupId":"OG016","value":"15"},{"groupId":"OG017","value":"18"},{"groupId":"OG018","value":"24"},{"groupId":"OG019","value":"34"},{"groupId":"OG020","value":"17"},{"groupId":"OG021","value":"38"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","lowerLimit":"2.6","upperLimit":"23.4"},{"groupId":"OG001","value":"4.8","lowerLimit":"0.5","upperLimit":"17.3"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"9.9"},{"groupId":"OG003","value":"4.3","lowerLimit":"0.5","upperLimit":"15.9"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"9.5"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"9.9"},{"groupId":"OG006","value":"25.8","lowerLimit":"15.7","upperLimit":"38.5"},{"groupId":"OG007","value":"8.1","lowerLimit":"3.0","upperLimit":"17.2"},{"groupId":"OG008","value":"8.6","lowerLimit":"4.3","upperLimit":"15.4"},{"groupId":"OG009","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"No efficacy data were collected as the module was prematurely discontinued by the sponsor for strategic reasons. At the time of decision to discontinue the module, only a single participant had received treatment, and only safety data were collected on that participant."},{"groupId":"OG010","value":"4.3","lowerLimit":"0.5","upperLimit":"15.9"},{"groupId":"OG011","value":"0","lowerLimit":"0.0","upperLimit":"22.6"},{"groupId":"OG012","value":"4.0","lowerLimit":"0.4","upperLimit":"14.7"},{"groupId":"OG013","value":"21.7","lowerLimit":"11.0","upperLimit":"36.6"},{"groupId":"OG014","value":"35.0","lowerLimit":"20.7","upperLimit":"51.8"},{"groupId":"OG015","value":"22.7","lowerLimit":"11.5","upperLimit":"38.1"},{"groupId":"OG016","value":"0","lowerLimit":"0.0","upperLimit":"14.2"},{"groupId":"OG017","value":"16.7","lowerLimit":"6.3","upperLimit":"33.4"},{"groupId":"OG018","value":"8.3","lowerLimit":"2.2","upperLimit":"20.7"},{"groupId":"OG019","value":"0","lowerLimit":"0.0","upperLimit":"6.5"},{"groupId":"OG020","value":"11.8","lowerLimit":"3.2","upperLimit":"28.4"},{"groupId":"OG021","value":"2.6","lowerLimit":"0.3","upperLimit":"9.9"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"The OS is defined as the time from the first dose of any study drug until death due to any cause regardless of whether the participant withdraws from study treatment or receives subsequent cancer therapy. The overall survival was analyzed using the Kaplan-Meier method.","populationDescription":"Intention to treat (ITT) analysis population included all enrolled participants who received at least 1 dose of the study drug and were analyzed according to their assigned cohort and planned treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"80% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Every 3 months after safety follow-up visit (90 days after study drug discontinuation) until planned database lock for a module (either 12 months after last participant has started treatment or when 75% of participants died) (approximately up to 2 years)","groups":[{"id":"OG000","title":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) received IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed."},{"id":"OG001","title":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations in liver kinase B1 (LKB1) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG002","title":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG003","title":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG004","title":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG005","title":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG006","title":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who are ataxia telangiectasia mutated (ATM)-deficiecy received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG007","title":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG008","title":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG009","title":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","description":"Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) received IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG010","title":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants with high expression of cluster of differentiation 73 (CD73) received IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG011","title":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG012","title":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG013","title":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations received IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG014","title":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours harbour selected HER2 mutations received IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG015","title":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG016","title":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","description":"Participants who are ATM-deficient or with detectable aberrations in the ATM gene received oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG017","title":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG018","title":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG019","title":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG020","title":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG021","title":"Module 11 Cohort C.11.240: AZD6738 240 mg","description":"Participants, independent of their molecular aberration status, received oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"31"},{"groupId":"OG007","value":"38"},{"groupId":"OG008","value":"58"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"23"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"25"},{"groupId":"OG013","value":"23"},{"groupId":"OG014","value":"20"},{"groupId":"OG015","value":"22"},{"groupId":"OG016","value":"15"},{"groupId":"OG017","value":"19"},{"groupId":"OG018","value":"24"},{"groupId":"OG019","value":"34"},{"groupId":"OG020","value":"17"},{"groupId":"OG021","value":"38"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.63","lowerLimit":"5.26","upperLimit":"15.97"},{"groupId":"OG001","value":"5.75","lowerLimit":"5.29","upperLimit":"10.84"},{"groupId":"OG002","value":"7.16","lowerLimit":"4.93","upperLimit":"10.28"},{"groupId":"OG003","value":"15.51","lowerLimit":"9.33","upperLimit":"20.86"},{"groupId":"OG004","value":"6.01","lowerLimit":"3.55","upperLimit":"6.51"},{"groupId":"OG005","value":"11.20","lowerLimit":"9.72","upperLimit":"12.55"},{"groupId":"OG006","value":"15.80","lowerLimit":"14.16","upperLimit":"22.80"},{"groupId":"OG007","value":"10.22","lowerLimit":"5.82","upperLimit":"11.30"},{"groupId":"OG008","value":"11.37","lowerLimit":"9.13","upperLimit":"15.80"},{"groupId":"OG009","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"No efficacy data were collected as the module was prematurely discontinued by the sponsor for strategic reasons. At the time of decision to discontinue the module, only a single participant had received treatment, and only safety data were collected on that participant."},{"groupId":"OG010","value":"10.97","lowerLimit":"7.59","upperLimit":"15.74"},{"groupId":"OG011","value":"7.06","lowerLimit":"4.90","upperLimit":"11.99"},{"groupId":"OG012","value":"12.78","lowerLimit":"7.39","upperLimit":"20.96"},{"groupId":"OG013","value":"9.53","lowerLimit":"6.57","upperLimit":"12.42"},{"groupId":"OG014","value":"10.61","lowerLimit":"8.90","upperLimit":"20.60"},{"groupId":"OG015","value":"14.19","lowerLimit":"11.86","upperLimit":"19.88"},{"groupId":"OG016","value":"14.23","lowerLimit":"6.08","upperLimit":"17.18"},{"groupId":"OG017","value":"7.95","lowerLimit":"5.59","upperLimit":"8.64"},{"groupId":"OG018","value":"12.91","lowerLimit":"7.39","upperLimit":"20.50"},{"groupId":"OG019","value":"5.95","lowerLimit":"4.01","upperLimit":"10.05"},{"groupId":"OG020","value":"7.03","lowerLimit":"4.37","upperLimit":"12.71"},{"groupId":"OG021","value":"6.60","lowerLimit":"5.85","upperLimit":"9.13"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) Per RECIST v1.1","description":"The PFS is defined as time from first dose of any study drug until date of objective disease progression (PD) per RECIST v1.1 or death by any cause, regardless of whether the participant withdraws from study therapy or receives another anti-cancer therapy prior to progression. The PD is defined as a \\>= 20% increase in the sum of diameters of TLs and an absolute increase of \\>= 5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters, or unequivocal progression of existing NTL. The PFS was analyzed using the Kaplan-Meier method","populationDescription":"The ITT analysis population included all enrolled participants who received at least 1 dose of the study drug and were analyzed according to their assigned cohort and planned treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"80% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Every 3 months after safety follow-up visit (90 days after study drug discontinuation) until planned database lock for a module (either 12 months after last participant has started treatment or when 75% of participants died) (approximately up to 2 years)","groups":[{"id":"OG000","title":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) received IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed."},{"id":"OG001","title":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations in liver kinase B1 (LKB1) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG002","title":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG003","title":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG004","title":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG005","title":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG006","title":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who are ataxia telangiectasia mutated (ATM)-deficiecy received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG007","title":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG008","title":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG009","title":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","description":"Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) received IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG010","title":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants with high expression of cluster of differentiation 73 (CD73) received IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG011","title":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG012","title":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG013","title":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations received IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG014","title":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours harbour selected HER2 mutations received IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG015","title":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG016","title":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","description":"Participants who are ATM-deficient or with detectable aberrations in the ATM gene received oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG017","title":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG018","title":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG019","title":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG020","title":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG021","title":"Module 11 Cohort C.11.240: AZD6738 240 mg","description":"Participants, independent of their molecular aberration status, received oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"31"},{"groupId":"OG007","value":"38"},{"groupId":"OG008","value":"58"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"23"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"25"},{"groupId":"OG013","value":"23"},{"groupId":"OG014","value":"20"},{"groupId":"OG015","value":"22"},{"groupId":"OG016","value":"15"},{"groupId":"OG017","value":"19"},{"groupId":"OG018","value":"24"},{"groupId":"OG019","value":"34"},{"groupId":"OG020","value":"17"},{"groupId":"OG021","value":"38"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.79","lowerLimit":"1.41","upperLimit":"5.26"},{"groupId":"OG001","value":"1.41","lowerLimit":"1.38","upperLimit":"1.81"},{"groupId":"OG002","value":"3.38","lowerLimit":"2.10","upperLimit":"4.93"},{"groupId":"OG003","value":"4.17","lowerLimit":"2.69","upperLimit":"4.37"},{"groupId":"OG004","value":"1.68","lowerLimit":"1.64","upperLimit":"2.99"},{"groupId":"OG005","value":"3.09","lowerLimit":"2.83","upperLimit":"6.14"},{"groupId":"OG006","value":"7.43","lowerLimit":"5.59","upperLimit":"9.43"},{"groupId":"OG007","value":"2.96","lowerLimit":"1.91","upperLimit":"3.09"},{"groupId":"OG008","value":"4.21","lowerLimit":"3.02","upperLimit":"4.96"},{"groupId":"OG009","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"No efficacy data were collected as the module was prematurely discontinued by the sponsor for strategic reasons. At the time of decision to discontinue the module, only a single participant had received treatment, and only safety data were collected on that participant."},{"groupId":"OG010","value":"1.61","lowerLimit":"1.41","upperLimit":"2.76"},{"groupId":"OG011","value":"1.41","lowerLimit":"1.35","upperLimit":"1.81"},{"groupId":"OG012","value":"2.69","lowerLimit":"1.74","upperLimit":"4.17"},{"groupId":"OG013","value":"2.83","lowerLimit":"2.33","upperLimit":"5.45"},{"groupId":"OG014","value":"5.52","lowerLimit":"5.32","upperLimit":"5.72"},{"groupId":"OG015","value":"4.17","lowerLimit":"2.56","upperLimit":"9.36"},{"groupId":"OG016","value":"3.42","lowerLimit":"2.14","upperLimit":"7.62"},{"groupId":"OG017","value":"1.48","lowerLimit":"1.41","upperLimit":"2.23"},{"groupId":"OG018","value":"3.68","lowerLimit":"2.83","upperLimit":"7.33"},{"groupId":"OG019","value":"1.68","lowerLimit":"1.61","upperLimit":"2.56"},{"groupId":"OG020","value":"2.00","lowerLimit":"1.71","upperLimit":"2.79"},{"groupId":"OG021","value":"2.86","lowerLimit":"2.73","upperLimit":"3.02"}]}]}]},{"type":"SECONDARY","title":"Best Percentage Change From Baseline in Tumour Size","description":"The best percentage change in tumour size from baseline i.e. the maximum reduction from baseline or the minimum increase from baseline in absence of a reduction from baseline based on all post baseline assessments is reported. Tumour size is sum of the longest diameters (or short axis measurements for lymph nodes) of the target lesions. Baseline was defined as last evaluable assessment prior to starting treatment. The percentage change in target lesion tumour size at each week X for which data are available was obtained for each participant taking the difference between the sum of the target lesions at each week X and the sum of the target lesions at baseline divided by the sum of the target lesions at baseline multiplied by 100 (i.e. \\[week X - baseline\\]/baseline \\* 100).","populationDescription":"Evaluable for response population included all dosed participants who had measurable disease at baseline and who were analyzed according to their assigned cohort and planned treatment. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percent Change in Tumor Size","timeFrame":"Baseline (<=28 days prior to starting treatment) then every 6 weeks for first 24 weeks relative to the date of first dose/combination therapy (Cycle 1 Day 1), then every 8 weeks (except Module 6)/9 weeks (Module 6) thereafter (approximately up to 2 years)","groups":[{"id":"OG000","title":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) received IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed."},{"id":"OG001","title":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations in liver kinase B1 (LKB1) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG002","title":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG003","title":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG004","title":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG005","title":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG006","title":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who are ataxia telangiectasia mutated (ATM)-deficiecy received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG007","title":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG008","title":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG009","title":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","description":"Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) received IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG010","title":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants with high expression of cluster of differentiation 73 (CD73) received IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG011","title":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG012","title":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG013","title":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations received IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG014","title":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours harbour selected HER2 mutations received IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG015","title":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG016","title":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","description":"Participants who are ATM-deficient or with detectable aberrations in the ATM gene received oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG017","title":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG018","title":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG019","title":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG020","title":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG021","title":"Module 11 Cohort C.11.240: AZD6738 240 mg","description":"Participants, independent of their molecular aberration status, received oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"31"},{"groupId":"OG007","value":"37"},{"groupId":"OG008","value":"58"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"23"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"25"},{"groupId":"OG013","value":"23"},{"groupId":"OG014","value":"20"},{"groupId":"OG015","value":"22"},{"groupId":"OG016","value":"15"},{"groupId":"OG017","value":"17"},{"groupId":"OG018","value":"23"},{"groupId":"OG019","value":"34"},{"groupId":"OG020","value":"17"},{"groupId":"OG021","value":"38"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.79","spread":"25.706"},{"groupId":"OG001","value":"10.24","spread":"25.197"},{"groupId":"OG002","value":"7.19","spread":"21.082"},{"groupId":"OG003","value":"-3.55","spread":"20.879"},{"groupId":"OG004","value":"16.36","spread":"20.732"},{"groupId":"OG005","value":"3.06","spread":"19.015"},{"groupId":"OG006","value":"-10.12","spread":"33.560"},{"groupId":"OG007","value":"3.39","spread":"29.846"},{"groupId":"OG008","value":"-0.03","spread":"29.952"},{"groupId":"OG009","value":"NA","spread":"NA","comment":"No efficacy data were collected as the module was prematurely discontinued by the sponsor for strategic reasons. At the time of decision to discontinue the module, only a single participant had received treatment, and only safety data were collected on that participant."},{"groupId":"OG010","value":"15.15","spread":"24.412"},{"groupId":"OG011","value":"19.55","spread":"21.537"},{"groupId":"OG012","value":"6.62","spread":"29.231"},{"groupId":"OG013","value":"-14.15","spread":"35.815"},{"groupId":"OG014","value":"-32.22","spread":"35.655"},{"groupId":"OG015","value":"-8.62","spread":"38.546"},{"groupId":"OG016","value":"-6.40","spread":"17.207"},{"groupId":"OG017","value":"8.96","spread":"46.410"},{"groupId":"OG018","value":"-2.59","spread":"27.957"},{"groupId":"OG019","value":"15.88","spread":"34.908"},{"groupId":"OG020","value":"19.74","spread":"43.830"},{"groupId":"OG021","value":"-1.14","spread":"22.354"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Control (DC) Per RECIST v1.1","description":"Module (M) 1, 4, 5, 6, 7, 8, 9, 11: DCR at 12 and 24 weeks is defined as percentage of participants who have best overall response (BoR) of CR or PR in first 13/25 weeks, respectively, post start of any study drug or with duration of SD for at least 11/23 weeks, respectively, after start of any study drug. M2, M3, M10: DCR at 12 and 24 weeks is defined as percentage of participants who have BoR of CR or PR within first 100 days (M2, M3, M10) or 184 days (M2, M3, M10) after start of any study drug, or have SD lasting at least 86 days (M2)/82 days (M3, M10), respectively, or 170 days (M2)/166 days (M3, M10), respectively, post start of any study drug. CR is defined as disappearance of all TL and NTLs, and any pathological lymph node (whether target or nontarget) must have reduction in short axis to \\<10 mm. PR is defined as at least 30% decrease in sum of diameters of TLs, taking as reference baseline sum diameters, as long as criteria for PD are not met.","populationDescription":"Evaluable for response population included all dosed participants who had measurable disease at baseline and who were analyzed according to their assigned cohort and planned treatment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"80% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"At 12 and 24 weeks after the start of study drug","groups":[{"id":"OG000","title":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) received IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed."},{"id":"OG001","title":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations in liver kinase B1 (LKB1) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG002","title":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG003","title":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG004","title":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG005","title":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG006","title":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who are ataxia telangiectasia mutated (ATM)-deficiecy received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG007","title":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG008","title":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG009","title":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","description":"Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) received IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG010","title":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants with high expression of cluster of differentiation 73 (CD73) received IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG011","title":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG012","title":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG013","title":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations received IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG014","title":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours harbour selected HER2 mutations received IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG015","title":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG016","title":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","description":"Participants who are ATM-deficient or with detectable aberrations in the ATM gene received oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG017","title":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG018","title":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG019","title":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG020","title":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG021","title":"Module 11 Cohort C.11.240: AZD6738 240 mg","description":"Participants, independent of their molecular aberration status, received oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"31"},{"groupId":"OG007","value":"37"},{"groupId":"OG008","value":"58"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"23"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"25"},{"groupId":"OG013","value":"23"},{"groupId":"OG014","value":"20"},{"groupId":"OG015","value":"22"},{"groupId":"OG016","value":"15"},{"groupId":"OG017","value":"18"},{"groupId":"OG018","value":"24"},{"groupId":"OG019","value":"34"},{"groupId":"OG020","value":"17"},{"groupId":"OG021","value":"38"}]}],"classes":[{"title":"At 12 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"38.1","lowerLimit":"23.6","upperLimit":"54.4"},{"groupId":"OG001","value":"9.5","lowerLimit":"2.6","upperLimit":"23.4"},{"groupId":"OG002","value":"45.5","lowerLimit":"30.5","upperLimit":"61.1"},{"groupId":"OG003","value":"52.2","lowerLimit":"37.0","upperLimit":"67.0"},{"groupId":"OG004","value":"13.0","lowerLimit":"4.9","upperLimit":"26.8"},{"groupId":"OG005","value":"40.9","lowerLimit":"26.4","upperLimit":"56.8"},{"groupId":"OG006","value":"67.7","lowerLimit":"54.7","upperLimit":"78.9"},{"groupId":"OG007","value":"54.1","lowerLimit":"42.3","upperLimit":"65.5"},{"groupId":"OG008","value":"58.6","lowerLimit":"49.4","upperLimit":"67.4"},{"groupId":"OG009","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"No efficacy data were collected as the module was prematurely discontinued by the sponsor for strategic reasons. At the time of decision to discontinue the module, only a single participant had received treatment, and only safety data were collected on that participant."},{"groupId":"OG010","value":"34.8","lowerLimit":"21.4","upperLimit":"50.3"},{"groupId":"OG011","value":"22.2","lowerLimit":"6.1","upperLimit":"49.0"},{"groupId":"OG012","value":"56.0","lowerLimit":"41.3","upperLimit":"69.9"},{"groupId":"OG013","value":"56.5","lowerLimit":"41.1","upperLimit":"71.0"},{"groupId":"OG014","value":"70.0","lowerLimit":"53.3","upperLimit":"83.4"},{"groupId":"OG015","value":"63.6","lowerLimit":"47.7","upperLimit":"77.5"},{"groupId":"OG016","value":"60.0","lowerLimit":"40.4","upperLimit":"77.4"},{"groupId":"OG017","value":"22.2","lowerLimit":"10.1","upperLimit":"39.6"},{"groupId":"OG018","value":"58.3","lowerLimit":"43.3","upperLimit":"72.3"},{"groupId":"OG019","value":"32.4","lowerLimit":"21.7","upperLimit":"44.7"},{"groupId":"OG020","value":"41.2","lowerLimit":"24.6","upperLimit":"59.4"},{"groupId":"OG021","value":"60.5","lowerLimit":"48.8","upperLimit":"71.3"}]}]},{"title":"At 24 weeks","categories":[{"measurements":[{"groupId":"OG000","value":"19.0","lowerLimit":"8.6","upperLimit":"34.5"},{"groupId":"OG001","value":"9.5","lowerLimit":"2.6","upperLimit":"23.4"},{"groupId":"OG002","value":"13.6","lowerLimit":"5.1","upperLimit":"27.9"},{"groupId":"OG003","value":"26.1","lowerLimit":"14.3","upperLimit":"41.3"},{"groupId":"OG004","value":"0","lowerLimit":"0.0","upperLimit":"9.5"},{"groupId":"OG005","value":"27.3","lowerLimit":"15.0","upperLimit":"43.0"},{"groupId":"OG006","value":"58.1","lowerLimit":"45.0","upperLimit":"70.3"},{"groupId":"OG007","value":"27.0","lowerLimit":"17.5","upperLimit":"38.5"},{"groupId":"OG008","value":"34.5","lowerLimit":"26.2","upperLimit":"43.7"},{"groupId":"OG009","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"No efficacy data were collected as the module was prematurely discontinued by the sponsor for strategic reasons. At the time of decision to discontinue the module, only a single participant had received treatment, and only safety data were collected on that participant."},{"groupId":"OG010","value":"8.7","lowerLimit":"2.3","upperLimit":"21.5"},{"groupId":"OG011","value":"11.1","lowerLimit":"1.2","upperLimit":"36.8"},{"groupId":"OG012","value":"24.0","lowerLimit":"13.1","upperLimit":"38.3"},{"groupId":"OG013","value":"34.8","lowerLimit":"21.4","upperLimit":"50.3"},{"groupId":"OG014","value":"60.0","lowerLimit":"43.3","upperLimit":"75.1"},{"groupId":"OG015","value":"45.5","lowerLimit":"30.5","upperLimit":"61.1"},{"groupId":"OG016","value":"40.0","lowerLimit":"22.6","upperLimit":"59.6"},{"groupId":"OG017","value":"16.7","lowerLimit":"6.3","upperLimit":"33.4"},{"groupId":"OG018","value":"33.3","lowerLimit":"20.5","upperLimit":"48.4"},{"groupId":"OG019","value":"17.6","lowerLimit":"9.5","upperLimit":"28.9"},{"groupId":"OG020","value":"23.5","lowerLimit":"10.7","upperLimit":"41.6"},{"groupId":"OG021","value":"26.3","lowerLimit":"17.0","upperLimit":"37.6"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR) Per RECIST v1.1","description":"The DoR is defined as the time from the first documented confirmed response (CR or PR) until the first documented PD or death in the absence of disease progression. The CR is defined as disappearance of all TLs and NTLs, and any pathological lymph node (whether target or nontarget) must have reduction in short axis to \\<10 mm. The PR is defined as at least a 30 decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters, as long as criteria for PD are not met. The PD is defined as a \\>=20% increase in the sum of diameters of TLs and an absolute increase of \\>=5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters, or unequivocal progression of existing NTL. The DoR was analyzed using the Kaplan-Meier method.","populationDescription":"Evaluable for response population included all dosed participants who had measurable disease at baseline and who were analyzed according to their assigned cohort and planned treatment. The DoR was assessed for only those participants who had OR. Here, number of participants denotes those participants who had OR (confirmed CR or PR).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"Months","timeFrame":"Baseline (<=28 days before treatment), then every 6 weeks for 24 weeks from Cycle 1 Day 1, then every 8 weeks (every 9 weeks in Module 6) until disease progression or 90 days after study drug discontinuation (approximately 2 years)","groups":[{"id":"OG000","title":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) received IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed."},{"id":"OG001","title":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations in liver kinase B1 (LKB1) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG002","title":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG003","title":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG004","title":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG005","title":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG006","title":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who are ataxia telangiectasia mutated (ATM)-deficiecy received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG007","title":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG008","title":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG009","title":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","description":"Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) received IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG010","title":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants with high expression of cluster of differentiation 73 (CD73) received IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG011","title":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG012","title":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG013","title":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations received IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG014","title":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours harbour selected HER2 mutations received IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG015","title":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG016","title":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","description":"Participants who are ATM-deficient or with detectable aberrations in the ATM gene received oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG017","title":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG018","title":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG019","title":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG020","title":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG021","title":"Module 11 Cohort C.11.240: AZD6738 240 mg","description":"Participants, independent of their molecular aberration status, received oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"5"},{"groupId":"OG014","value":"7"},{"groupId":"OG015","value":"5"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"3"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"2"},{"groupId":"OG021","value":"1"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Number of responders were less than 3, hence median and the quartiles of were not calculated."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Number of responders were less than 3, hence median and the quartiles were not calculated."},{"groupId":"OG003","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Number of responders were less than 3, hence median and the quartiles were not calculated."},{"groupId":"OG006","value":"6.57","lowerLimit":"5.95","upperLimit":"13.24"},{"groupId":"OG007","value":"10.45","lowerLimit":"3.94","upperLimit":"10.45"},{"groupId":"OG008","value":"34.83","lowerLimit":"7.85","upperLimit":"34.83"},{"groupId":"OG010","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Number of responders were less than 3, hence median and the quartiles were not calculated."},{"groupId":"OG012","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Number of responders were less than 3, hence median and the quartiles were not calculated."},{"groupId":"OG013","value":"6.60","lowerLimit":"4.17","upperLimit":"NA","comment":"Third quartile was not calculated as percentage of events associated with that quartile was not met by end of study follow-up."},{"groupId":"OG014","value":"4.14","lowerLimit":"2.79","upperLimit":"5.32"},{"groupId":"OG015","value":"11.10","lowerLimit":"6.18","upperLimit":"19.68"},{"groupId":"OG017","value":"NA","lowerLimit":"1.87","upperLimit":"NA","comment":"Median and third quartile were not calculated as percentage of events associated with that median and quartile were not met by end of study follow-up."},{"groupId":"OG018","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Number of responders were less than 3, hence median and the quartiles were not calculated."},{"groupId":"OG020","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Number of responders were less than 3, hence median and the quartiles were not calculated."},{"groupId":"OG021","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Number of responders were less than 3, hence median and the quartiles were not calculated."}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)","description":"An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.","populationDescription":"Safety analysis set included participants who received at least 1 dose of study drug and who were analyzed according to the actual treatment received and corresponding assigned cohort.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 thorugh 58.6 months (maximum observed duration)","groups":[{"id":"OG000","title":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) received IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed."},{"id":"OG001","title":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations in liver kinase B1 (LKB1) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG002","title":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG003","title":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG004","title":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG005","title":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG006","title":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who are ataxia telangiectasia mutated (ATM)-deficiecy received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG007","title":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG008","title":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG009","title":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","description":"Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) received IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG010","title":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants with high expression of cluster of differentiation 73 (CD73) received IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG011","title":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG012","title":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG013","title":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations received IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG014","title":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours harbour selected HER2 mutations received IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG015","title":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG016","title":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","description":"Participants who are ATM-deficient or with detectable aberrations in the ATM gene received oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG017","title":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG018","title":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG019","title":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG020","title":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG021","title":"Module 11 Cohort C.11.240: AZD6738 240 mg","description":"Participants, independent of their molecular aberration status, received oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"31"},{"groupId":"OG007","value":"38"},{"groupId":"OG008","value":"58"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"23"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"25"},{"groupId":"OG013","value":"23"},{"groupId":"OG014","value":"20"},{"groupId":"OG015","value":"22"},{"groupId":"OG016","value":"15"},{"groupId":"OG017","value":"19"},{"groupId":"OG018","value":"24"},{"groupId":"OG019","value":"34"},{"groupId":"OG020","value":"17"},{"groupId":"OG021","value":"38"}]}],"classes":[{"title":"Any TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"31"},{"groupId":"OG007","value":"35"},{"groupId":"OG008","value":"56"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"21"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"22"},{"groupId":"OG013","value":"23"},{"groupId":"OG014","value":"20"},{"groupId":"OG015","value":"21"},{"groupId":"OG016","value":"15"},{"groupId":"OG017","value":"17"},{"groupId":"OG018","value":"24"},{"groupId":"OG019","value":"32"},{"groupId":"OG020","value":"16"},{"groupId":"OG021","value":"38"}]}]},{"title":"Any TESAEs","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"17"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"7"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"10"},{"groupId":"OG014","value":"10"},{"groupId":"OG015","value":"7"},{"groupId":"OG016","value":"7"},{"groupId":"OG017","value":"7"},{"groupId":"OG018","value":"13"},{"groupId":"OG019","value":"12"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"17"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs","description":"Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. Abnormal clinical laboratory parameters defined as any abnormal finding during analysis of hematology, clinical chemistry, and urinalysis.","populationDescription":"Safety analysis set included participants who received at least 1 dose of study drug and who were analyzed according to the actual treatment received and corresponding assigned cohort.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 thorugh 58.6 months (maximum observed duration)","groups":[{"id":"OG000","title":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) received IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed."},{"id":"OG001","title":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations in liver kinase B1 (LKB1) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG002","title":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG003","title":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG004","title":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG005","title":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG006","title":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who are ataxia telangiectasia mutated (ATM)-deficiecy received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG007","title":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG008","title":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG009","title":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","description":"Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) received IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG010","title":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants with high expression of cluster of differentiation 73 (CD73) received IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG011","title":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG012","title":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG013","title":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations received IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG014","title":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours harbour selected HER2 mutations received IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG015","title":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG016","title":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","description":"Participants who are ATM-deficient or with detectable aberrations in the ATM gene received oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG017","title":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG018","title":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG019","title":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG020","title":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG021","title":"Module 11 Cohort C.11.240: AZD6738 240 mg","description":"Participants, independent of their molecular aberration status, received oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"31"},{"groupId":"OG007","value":"38"},{"groupId":"OG008","value":"58"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"23"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"25"},{"groupId":"OG013","value":"23"},{"groupId":"OG014","value":"20"},{"groupId":"OG015","value":"22"},{"groupId":"OG016","value":"15"},{"groupId":"OG017","value":"19"},{"groupId":"OG018","value":"24"},{"groupId":"OG019","value":"34"},{"groupId":"OG020","value":"17"},{"groupId":"OG021","value":"38"}]}],"classes":[{"title":"Anaemia","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"19"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"7"},{"groupId":"OG014","value":"12"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"12"},{"groupId":"OG017","value":"8"},{"groupId":"OG018","value":"12"},{"groupId":"OG019","value":"5"},{"groupId":"OG020","value":"7"},{"groupId":"OG021","value":"15"}]}]},{"title":"Thrombocytopenia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"3"},{"groupId":"OG017","value":"5"},{"groupId":"OG018","value":"10"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"2"},{"groupId":"OG021","value":"2"}]}]},{"title":"Hyponatraemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"2"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"3"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"4"}]}]},{"title":"Hypokalaemia","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"3"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"4"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"2"}]}]},{"title":"Aspartate aminotransferase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"4"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"2"},{"groupId":"OG021","value":"2"}]}]},{"title":"Blood creatinine increased","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"2"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"2"}]}]},{"title":"Hypoalbuminaemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"2"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"5"}]}]},{"title":"Platelet count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"4"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"4"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"6"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Alanine aminotransferase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"2"},{"groupId":"OG021","value":"3"}]}]},{"title":"C-reactive protein increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"2"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"2"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"4"}]}]},{"title":"Hypomagnesaemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"3"}]}]},{"title":"Hyperglycaemia","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Lymphocyte count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"2"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Lipase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Neutrophil count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"4"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"2"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Blood alkaline phosphatase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Hypophosphataemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"5"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"4"}]}]},{"title":"Neutropenia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"2"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"2"}]}]},{"title":"White blood cell count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"4"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"2"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"2"}]}]},{"title":"Amylase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Gamma-glutamyltransferase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"2"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Hypercalcaemia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"2"},{"groupId":"OG021","value":"3"}]}]},{"title":"Hypocalcaemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"2"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Blood bilirubin increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"1"}]}]},{"title":"Hyperkalaemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"2"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Lymphopenia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"2"},{"groupId":"OG021","value":"1"}]}]},{"title":"Blood thyroid stimulating hormone increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"1"}]}]},{"title":"Hypoglycaemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Liver function test increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Blood phosphorus decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Febrile neutropenia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Pancytopenia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"White blood cell count increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Blood creatine phosphokinase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"1"}]}]},{"title":"Hepatic enzyme increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Hypertransaminasaemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"1"}]}]},{"title":"Leukopenia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Proteinuria","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Blood albumin decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Blood iron decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Blood lactate dehydrogenase decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"International normalised ratio increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Megakaryocytes abnormal","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Normocytic anaemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Prothrombin time prolonged","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Hypothyroidism","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"3"},{"groupId":"OG016","value":"2"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"2"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Hepatic cytolysis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Blood lactate dehydrogenase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Pollakiuria","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"2"}]}]},{"title":"Blood urea increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Haematuria","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Renal failure","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Hyperthyroidism","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Myocardial infarction","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Adrenal insufficiency","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Creatinine renal clearance decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Eosinophil count increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Haemoglobin decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Hypernatraemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Lymphadenopathy","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Neutrophil count increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Pancreatitis","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Platelet count increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Troponin increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Type 1 diabetes mellitus","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Vitamin B12 deficiency","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Azotaemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Bilirubin conjugated increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Blood calcium decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Blood calcium increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Blood chloride decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Blood chloride increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Blood fibrinogen decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Blood fibrinogen increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Blood glucose increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Blood magnesium decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Blood phosphorus increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Blood sodium decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Blood thrombin increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Brain natriuretic peptide increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Coagulation time prolonged","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Coagulopathy","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Cushingoid","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Febrile bone marrow aplasia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Folate deficiency","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Haematocrit increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Haptoglobin increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Hepatocellular injury","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Hydronephrosis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Hypercholesterolaemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Hyperlipasaemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Hypophysitis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Iron deficiency","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Pancreatitis acute","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Procalcitonin increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Protein total decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Prothrombin time ratio increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Red blood cell count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Red blood cells urine positive","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Renal disorder","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Thyroiditis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Tri-iodothyronine increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Troponin T increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Type 2 diabetes mellitus","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Abnormal Vital Signs Reported as TEAEs","description":"Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (blood pressure, pulse rate, temperature, and respiration rate).","populationDescription":"Safety analysis set included participants who received at least 1 dose of study drug and who were analyzed according to the actual treatment received and corresponding assigned cohort.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 thorugh 58.6 months (maximum observed duration)","groups":[{"id":"OG000","title":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) received IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed."},{"id":"OG001","title":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations in liver kinase B1 (LKB1) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG002","title":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG003","title":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG004","title":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG005","title":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG006","title":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who are ataxia telangiectasia mutated (ATM)-deficiecy received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG007","title":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG008","title":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG009","title":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","description":"Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) received IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG010","title":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants with high expression of cluster of differentiation 73 (CD73) received IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG011","title":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG012","title":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG013","title":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations received IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG014","title":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours harbour selected HER2 mutations received IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG015","title":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG016","title":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","description":"Participants who are ATM-deficient or with detectable aberrations in the ATM gene received oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG017","title":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG018","title":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG019","title":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG020","title":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG021","title":"Module 11 Cohort C.11.240: AZD6738 240 mg","description":"Participants, independent of their molecular aberration status, received oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"31"},{"groupId":"OG007","value":"38"},{"groupId":"OG008","value":"58"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"23"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"25"},{"groupId":"OG013","value":"23"},{"groupId":"OG014","value":"20"},{"groupId":"OG015","value":"22"},{"groupId":"OG016","value":"15"},{"groupId":"OG017","value":"19"},{"groupId":"OG018","value":"24"},{"groupId":"OG019","value":"34"},{"groupId":"OG020","value":"17"},{"groupId":"OG021","value":"38"}]}],"classes":[{"title":"Dyspnoea","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"6"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"6"},{"groupId":"OG015","value":"3"},{"groupId":"OG016","value":"3"},{"groupId":"OG017","value":"3"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"5"},{"groupId":"OG020","value":"2"},{"groupId":"OG021","value":"6"}]}]},{"title":"Hypotension","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"3"}]}]},{"title":"Hypertension","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"5"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Tachycardia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"4"}]}]},{"title":"Dyspnoea exertional","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"2"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Blood pressure increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Blood pressure systolic increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Bradycardia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Heart rate irregular","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Hypertensive crisis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs","description":"Number of participants with abnormal physical examination findings reported as TEAEs are reported. Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the pre-dose assessment was reported as an AE.","populationDescription":"Safety analysis set included participants who received at least 1 dose of study drug and who were analyzed according to the actual treatment received and corresponding assigned cohort.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 thorugh 58.6 months (maximum observed duration)","groups":[{"id":"OG000","title":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) received IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed."},{"id":"OG001","title":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations in liver kinase B1 (LKB1) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG002","title":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG003","title":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG004","title":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG005","title":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG006","title":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who are ataxia telangiectasia mutated (ATM)-deficiecy received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG007","title":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG008","title":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG009","title":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","description":"Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) received IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG010","title":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants with high expression of cluster of differentiation 73 (CD73) received IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG011","title":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG012","title":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG013","title":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations received IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG014","title":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours harbour selected HER2 mutations received IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG015","title":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG016","title":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","description":"Participants who are ATM-deficient or with detectable aberrations in the ATM gene received oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG017","title":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG018","title":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG019","title":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG020","title":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG021","title":"Module 11 Cohort C.11.240: AZD6738 240 mg","description":"Participants, independent of their molecular aberration status, received oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"31"},{"groupId":"OG007","value":"38"},{"groupId":"OG008","value":"58"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"23"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"25"},{"groupId":"OG013","value":"23"},{"groupId":"OG014","value":"20"},{"groupId":"OG015","value":"22"},{"groupId":"OG016","value":"15"},{"groupId":"OG017","value":"19"},{"groupId":"OG018","value":"24"},{"groupId":"OG019","value":"34"},{"groupId":"OG020","value":"17"},{"groupId":"OG021","value":"38"}]}],"classes":[{"title":"Weight decreased","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"5"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"5"},{"groupId":"OG016","value":"4"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"4"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"9"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"4"},{"groupId":"OG015","value":"3"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"3"},{"groupId":"OG020","value":"2"},{"groupId":"OG021","value":"9"}]}]},{"title":"Dizziness","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"4"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"2"},{"groupId":"OG020","value":"3"},{"groupId":"OG021","value":"3"}]}]},{"title":"Rash","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"3"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"2"},{"groupId":"OG017","value":"5"},{"groupId":"OG018","value":"5"},{"groupId":"OG019","value":"2"},{"groupId":"OG020","value":"2"},{"groupId":"OG021","value":"2"}]}]},{"title":"Dry skin","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"2"},{"groupId":"OG021","value":"1"}]}]},{"title":"Alopecia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"4"},{"groupId":"OG014","value":"7"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"2"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Dehydration","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Hypoxia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Myalgia","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"3"}]}]},{"title":"Rash maculo-papular","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"2"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Chronic obstructive pulmonary disease","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"2"}]}]},{"title":"Tremor","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"2"}]}]},{"title":"Erythema","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Rash pruritic","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Skin lesion","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Eczema","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Haematoma","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Skin hyperpigmentation","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Psoriasis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Skin exfoliation","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Skin irritation","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Decubitus ulcer","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Orthostatic hypotension","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Skin disorder","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Urticaria","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Vena cava thrombosis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Breath sounds","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Cardiac murmur","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Depressed level of consciousness","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Dermatitis acneiform","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Dermatitis allergic","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Dermatitis psoriasiform","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Ecchymosis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Lymphoedema","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Nail disorder","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Peripheral ischaemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"0"}]}]},{"title":"Petechiae","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Photosensitivity reaction","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"0"}]}]},{"title":"Rash erythematous","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Rash macular","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Rash papular","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Rash pustular","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Seborrhoeic dermatitis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Skin discolouration","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Skin induration","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Skin mass","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Skin ulcer","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Superior vena cava syndrome","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Transient ischaemic attack","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs","description":"Number of participants with abnormal ECGs reported as TEAEs are reported.","populationDescription":"Safety analysis set included participants who received at least 1 dose of study drug and who were analyzed according to the actual treatment received and corresponding assigned cohort.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 thorugh 58.6 months (maximum observed duration)","groups":[{"id":"OG000","title":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) received IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed."},{"id":"OG001","title":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations in liver kinase B1 (LKB1) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG002","title":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG003","title":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed."},{"id":"OG004","title":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG005","title":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG006","title":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who are ataxia telangiectasia mutated (ATM)-deficiecy received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG007","title":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG008","title":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG009","title":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","description":"Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) received IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG010","title":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants with high expression of cluster of differentiation 73 (CD73) received IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG011","title":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG012","title":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG013","title":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations received IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG014","title":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours harbour selected HER2 mutations received IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG015","title":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG016","title":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","description":"Participants who are ATM-deficient or with detectable aberrations in the ATM gene received oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG017","title":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG018","title":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria."},{"id":"OG019","title":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG020","title":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."},{"id":"OG021","title":"Module 11 Cohort C.11.240: AZD6738 240 mg","description":"Participants, independent of their molecular aberration status, received oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"31"},{"groupId":"OG007","value":"38"},{"groupId":"OG008","value":"58"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"23"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"25"},{"groupId":"OG013","value":"23"},{"groupId":"OG014","value":"20"},{"groupId":"OG015","value":"22"},{"groupId":"OG016","value":"15"},{"groupId":"OG017","value":"19"},{"groupId":"OG018","value":"24"},{"groupId":"OG019","value":"34"},{"groupId":"OG020","value":"17"},{"groupId":"OG021","value":"38"}]}],"classes":[{"title":"Sinus tachycardia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"5"}]}]},{"title":"Tachycardia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"2"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"1"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"1"},{"groupId":"OG021","value":"4"}]}]},{"title":"Atrial fibrillation","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"}]}]},{"title":"Cardiac failure","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Electrocardiogram QT prolonged","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"2"}]}]},{"title":"Cardiac arrest","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Arrhythmia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Ventricular extrasystoles","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Acute myocardial infarction","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Angina pectoris","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Atrial flutter","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Atrioventricular block second degree","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Bradycardia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"1"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Bundle branch block right","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Electrocardiogram RR interval prolonged","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Heart rate irregular","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Myocardial ischaemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Myocarditis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Myopericarditis","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]},{"title":"Supraventricular tachycardia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Day 1 through 61.55 months (maximum observed duration)","description":"An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","eventGroups":[{"id":"EG000","title":"Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) received IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed.","deathsNumAffected":18,"deathsNumAtRisk":21,"seriousNumAffected":10,"seriousNumAtRisk":21,"otherNumAffected":19,"otherNumAtRisk":21},{"id":"EG001","title":"Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants with detectable aberrations in liver kinase B1 (LKB1) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed.","deathsNumAffected":18,"deathsNumAtRisk":21,"seriousNumAffected":7,"seriousNumAtRisk":21,"otherNumAffected":19,"otherNumAtRisk":21},{"id":"EG002","title":"Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed.","deathsNumAffected":20,"deathsNumAtRisk":22,"seriousNumAffected":8,"seriousNumAtRisk":22,"otherNumAffected":19,"otherNumAtRisk":22},{"id":"EG003","title":"Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed.","deathsNumAffected":21,"deathsNumAtRisk":23,"seriousNumAffected":7,"seriousNumAtRisk":23,"otherNumAffected":21,"otherNumAtRisk":23},{"id":"EG004","title":"Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","deathsNumAffected":21,"deathsNumAtRisk":23,"seriousNumAffected":12,"seriousNumAtRisk":23,"otherNumAffected":22,"otherNumAtRisk":23},{"id":"EG005","title":"Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","deathsNumAffected":16,"deathsNumAtRisk":22,"seriousNumAffected":8,"seriousNumAtRisk":22,"otherNumAffected":19,"otherNumAtRisk":22},{"id":"EG006","title":"Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who are ataxia telangiectasia mutated (ATM)-deficiecy received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.","deathsNumAffected":28,"deathsNumAtRisk":31,"seriousNumAffected":11,"seriousNumAtRisk":31,"otherNumAffected":30,"otherNumAtRisk":31},{"id":"EG007","title":"Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.","deathsNumAffected":35,"deathsNumAtRisk":38,"seriousNumAffected":11,"seriousNumAtRisk":38,"otherNumAffected":34,"otherNumAtRisk":38},{"id":"EG008","title":"Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.","deathsNumAffected":48,"deathsNumAtRisk":58,"seriousNumAffected":17,"seriousNumAtRisk":58,"otherNumAffected":55,"otherNumAtRisk":58},{"id":"EG009","title":"Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg","description":"Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) received IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.","deathsNumAffected":0,"deathsNumAtRisk":1,"seriousNumAffected":0,"seriousNumAtRisk":1,"otherNumAffected":1,"otherNumAtRisk":1},{"id":"EG010","title":"Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants with high expression of cluster of differentiation 73 (CD73) received IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","deathsNumAffected":19,"deathsNumAtRisk":23,"seriousNumAffected":7,"seriousNumAtRisk":23,"otherNumAffected":19,"otherNumAtRisk":23},{"id":"EG011","title":"Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","deathsNumAffected":6,"deathsNumAtRisk":9,"seriousNumAffected":1,"seriousNumAtRisk":9,"otherNumAffected":5,"otherNumAtRisk":9},{"id":"EG012","title":"Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","deathsNumAffected":21,"deathsNumAtRisk":25,"seriousNumAffected":6,"seriousNumAtRisk":25,"otherNumAffected":22,"otherNumAtRisk":25},{"id":"EG013","title":"Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations received IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","deathsNumAffected":22,"deathsNumAtRisk":23,"seriousNumAffected":10,"seriousNumAtRisk":23,"otherNumAffected":23,"otherNumAtRisk":23},{"id":"EG014","title":"Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg","description":"Participants whose tumours harbour selected HER2 mutations received IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","deathsNumAffected":17,"deathsNumAtRisk":20,"seriousNumAffected":10,"seriousNumAtRisk":20,"otherNumAffected":20,"otherNumAtRisk":20},{"id":"EG015","title":"Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","deathsNumAffected":18,"deathsNumAtRisk":22,"seriousNumAffected":7,"seriousNumAtRisk":22,"otherNumAffected":20,"otherNumAtRisk":22},{"id":"EG016","title":"Module 8 Cohort A.8.ATM: Ceralasertib 240 mg","description":"Participants who are ATM-deficient or with detectable aberrations in the ATM gene received oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","deathsNumAffected":13,"deathsNumAtRisk":15,"seriousNumAffected":7,"seriousNumAtRisk":15,"otherNumAffected":15,"otherNumAtRisk":15},{"id":"EG017","title":"Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","deathsNumAffected":15,"deathsNumAtRisk":19,"seriousNumAffected":7,"seriousNumAtRisk":19,"otherNumAffected":17,"otherNumAtRisk":19},{"id":"EG018","title":"Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants who had progressive disease \\> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.","deathsNumAffected":17,"deathsNumAtRisk":24,"seriousNumAffected":13,"seriousNumAtRisk":24,"otherNumAffected":24,"otherNumAtRisk":24},{"id":"EG019","title":"Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.","deathsNumAffected":27,"deathsNumAtRisk":34,"seriousNumAffected":12,"seriousNumAtRisk":34,"otherNumAffected":30,"otherNumAtRisk":34},{"id":"EG020","title":"Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg","description":"Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.","deathsNumAffected":14,"deathsNumAtRisk":17,"seriousNumAffected":1,"seriousNumAtRisk":17,"otherNumAffected":16,"otherNumAtRisk":17},{"id":"EG021","title":"Module 11 Cohort C.11.240: AZD6738 240 mg","description":"Participants, independent of their molecular aberration status, received oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.","deathsNumAffected":27,"deathsNumAtRisk":38,"seriousNumAffected":17,"seriousNumAtRisk":38,"otherNumAffected":38,"otherNumAtRisk":38}],"seriousEvents":[{"term":"Normocytic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Klebsiella infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Parainfluenzae virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":22},{"groupId":"EG006","numEvents":3,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG008","numEvents":6,"numAffected":5,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":6,"numAffected":6,"numAtRisk":38}]},{"term":"Pneumonia aspiration","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Postoperative wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Respiratory syncytial virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":3,"numAffected":3,"numAtRisk":38}]},{"term":"Salmonellosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":1,"numAtRisk":38}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Urinary tract infection bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Procedural pneumothorax","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Scapula fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Autoimmune pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Skin abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Traumatic haemothorax","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Upper limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Cor pulmonale","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Immune-mediated myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Acute myeloid leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Altered state of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":3,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Renal artery thrombosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Myopericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Alveolitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":1,"numAtRisk":38}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":3,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":2,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Air embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Bone marrow failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Coagulopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Febrile bone marrow aplasia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Oesophageal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Rectal prolapse","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hepatic cytolysis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hypertransaminasaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Adenovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Covid-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Coronavirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Diarrhoea infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]}],"otherEvents":[{"term":"Herpes simplex","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":4,"numAffected":3,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":6,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":4,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"Pneumonia streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":5,"numAffected":3,"numAtRisk":38}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":4,"numAffected":3,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":5,"numAffected":4,"numAtRisk":23},{"groupId":"EG005","numEvents":6,"numAffected":6,"numAtRisk":22},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":31},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":4,"numAffected":3,"numAtRisk":15},{"groupId":"EG017","numEvents":5,"numAffected":5,"numAtRisk":19},{"groupId":"EG018","numEvents":12,"numAffected":9,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":3,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":3,"numAffected":3,"numAtRisk":19},{"groupId":"EG018","numEvents":5,"numAffected":3,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":4,"numAffected":2,"numAtRisk":38}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG005","numEvents":5,"numAffected":5,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":6,"numAffected":2,"numAtRisk":17},{"groupId":"EG021","numEvents":4,"numAffected":3,"numAtRisk":38}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":5,"numAffected":3,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":7,"numAffected":4,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":8,"numAffected":2,"numAtRisk":17},{"groupId":"EG021","numEvents":3,"numAffected":2,"numAtRisk":38}]},{"term":"Blood albumin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":5,"numAffected":4,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":1,"numAtRisk":38}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":4,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":1,"numAtRisk":38}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":3,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG008","numEvents":3,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":4,"numAffected":3,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":3,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":5,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"Blood iron decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Blood lactate dehydrogenase decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Blood phosphorus decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Blood pressure systolic increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":4,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":3,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":6,"numAffected":4,"numAtRisk":38}]},{"term":"Electrocardiogram qt prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":3,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":3,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":3,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Heart rate irregular","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":4,"numAffected":3,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":1,"numAtRisk":38}]},{"term":"Liver function test increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":5,"numAffected":3,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Megakaryocytes abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":6,"numAffected":4,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":2,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":5,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":5,"numAffected":4,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":8,"numAffected":4,"numAtRisk":15},{"groupId":"EG017","numEvents":3,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":11,"numAffected":5,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Prothrombin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Urine output decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG008","numEvents":12,"numAffected":10,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":5,"numAffected":5,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":6,"numAffected":5,"numAtRisk":22},{"groupId":"EG016","numEvents":4,"numAffected":4,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":4,"numAffected":4,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":10,"numAffected":9,"numAtRisk":38}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":6,"numAffected":4,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":2,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Cachexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":21},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":21},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG003","numEvents":8,"numAffected":8,"numAtRisk":23},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG005","numEvents":4,"numAffected":3,"numAtRisk":22},{"groupId":"EG006","numEvents":6,"numAffected":6,"numAtRisk":31},{"groupId":"EG007","numEvents":10,"numAffected":10,"numAtRisk":38},{"groupId":"EG008","numEvents":24,"numAffected":22,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":3,"numAffected":3,"numAtRisk":25},{"groupId":"EG013","numEvents":12,"numAffected":10,"numAtRisk":23},{"groupId":"EG014","numEvents":8,"numAffected":7,"numAtRisk":20},{"groupId":"EG015","numEvents":6,"numAffected":5,"numAtRisk":22},{"groupId":"EG016","numEvents":7,"numAffected":7,"numAtRisk":15},{"groupId":"EG017","numEvents":4,"numAffected":4,"numAtRisk":19},{"groupId":"EG018","numEvents":8,"numAffected":7,"numAtRisk":24},{"groupId":"EG019","numEvents":6,"numAffected":6,"numAtRisk":34},{"groupId":"EG020","numEvents":7,"numAffected":5,"numAtRisk":17},{"groupId":"EG021","numEvents":17,"numAffected":15,"numAtRisk":38}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":5,"numAffected":4,"numAtRisk":38},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":3,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":3,"numAffected":2,"numAtRisk":17},{"groupId":"EG021","numEvents":3,"numAffected":3,"numAtRisk":38}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":1,"numAtRisk":38}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":3,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":5,"numAffected":5,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":4,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":6,"numAffected":5,"numAtRisk":38}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":21},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":5,"numAffected":5,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":4,"numAffected":3,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":3,"numAffected":3,"numAtRisk":15},{"groupId":"EG017","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG018","numEvents":5,"numAffected":4,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":4,"numAffected":2,"numAtRisk":38}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":3,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":4,"numAffected":3,"numAtRisk":38}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":3,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":7,"numAffected":6,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":4,"numAffected":2,"numAtRisk":23},{"groupId":"EG014","numEvents":7,"numAffected":5,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":5,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":3,"numAffected":3,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":5,"numAffected":4,"numAtRisk":38}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":5,"numAffected":5,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":5,"numAffected":4,"numAtRisk":38}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":21},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":21},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG006","numEvents":11,"numAffected":8,"numAtRisk":31},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG008","numEvents":6,"numAffected":4,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":3,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":4,"numAffected":4,"numAtRisk":38}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":22},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":9,"numAffected":8,"numAtRisk":31},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG008","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG014","numEvents":4,"numAffected":3,"numAtRisk":20},{"groupId":"EG015","numEvents":5,"numAffected":5,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":4,"numAffected":4,"numAtRisk":38}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":5,"numAffected":4,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":3,"numAffected":2,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":3,"numAffected":3,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":4,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"Musculoskeletal discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":4,"numAffected":2,"numAtRisk":38}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":1,"numAtRisk":38}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":6,"numAffected":3,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":7,"numAtRisk":21},{"groupId":"EG001","numEvents":12,"numAffected":7,"numAtRisk":21},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":22},{"groupId":"EG003","numEvents":10,"numAffected":7,"numAtRisk":23},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG005","numEvents":5,"numAffected":4,"numAtRisk":22},{"groupId":"EG006","numEvents":11,"numAffected":10,"numAtRisk":31},{"groupId":"EG007","numEvents":10,"numAffected":9,"numAtRisk":38},{"groupId":"EG008","numEvents":22,"numAffected":19,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":3,"numAffected":3,"numAtRisk":25},{"groupId":"EG013","numEvents":9,"numAffected":7,"numAtRisk":23},{"groupId":"EG014","numEvents":20,"numAffected":12,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":16,"numAffected":12,"numAtRisk":15},{"groupId":"EG017","numEvents":9,"numAffected":8,"numAtRisk":19},{"groupId":"EG018","numEvents":14,"numAffected":12,"numAtRisk":24},{"groupId":"EG019","numEvents":6,"numAffected":5,"numAtRisk":34},{"groupId":"EG020","numEvents":7,"numAffected":7,"numAtRisk":17},{"groupId":"EG021","numEvents":21,"numAffected":15,"numAtRisk":38}]},{"term":"Balance disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Bell's palsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Disturbance in attention","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":22},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":5,"numAffected":5,"numAtRisk":38},{"groupId":"EG008","numEvents":11,"numAffected":9,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":4,"numAffected":4,"numAtRisk":25},{"groupId":"EG013","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG014","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG015","numEvents":4,"numAffected":4,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG020","numEvents":3,"numAffected":3,"numAtRisk":17},{"groupId":"EG021","numEvents":3,"numAffected":3,"numAtRisk":38}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":22},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":6,"numAffected":6,"numAtRisk":31},{"groupId":"EG007","numEvents":5,"numAffected":5,"numAtRisk":38},{"groupId":"EG008","numEvents":9,"numAffected":7,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":5,"numAffected":3,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":4,"numAffected":4,"numAtRisk":20},{"groupId":"EG015","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":7,"numAffected":3,"numAtRisk":34},{"groupId":"EG020","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG021","numEvents":11,"numAffected":9,"numAtRisk":38}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":2,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Hypotonia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":2,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Taste disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"Abnormal dreams","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hallucination","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":6,"numAffected":5,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Neuropsychological symptoms","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Panic attack","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Restlessness","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Urine odour abnormal","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":21},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":21},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG005","numEvents":10,"numAffected":8,"numAtRisk":22},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":31},{"groupId":"EG007","numEvents":6,"numAffected":6,"numAtRisk":38},{"groupId":"EG008","numEvents":9,"numAffected":9,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":3,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":4,"numAffected":3,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":3,"numAffected":3,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":8,"numAffected":5,"numAtRisk":38}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":21},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":23},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG005","numEvents":5,"numAffected":5,"numAtRisk":22},{"groupId":"EG006","numEvents":6,"numAffected":6,"numAtRisk":31},{"groupId":"EG007","numEvents":7,"numAffected":6,"numAtRisk":38},{"groupId":"EG008","numEvents":6,"numAffected":6,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":6,"numAffected":6,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG014","numEvents":5,"numAffected":5,"numAtRisk":20},{"groupId":"EG015","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG016","numEvents":3,"numAffected":3,"numAtRisk":15},{"groupId":"EG017","numEvents":3,"numAffected":3,"numAtRisk":19},{"groupId":"EG018","numEvents":3,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":3,"numAffected":3,"numAtRisk":34},{"groupId":"EG020","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG021","numEvents":6,"numAffected":6,"numAtRisk":38}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":2,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Emphysema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":22},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":2,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":4,"numAffected":3,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":3,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG021","numEvents":5,"numAffected":4,"numAtRisk":38}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":2,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":6,"numAffected":5,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":7,"numAffected":6,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":3,"numAffected":3,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":3,"numAffected":3,"numAtRisk":15},{"groupId":"EG017","numEvents":3,"numAffected":3,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pulmonary hypertension","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Pulmonary pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Upper-airway cough syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG014","numEvents":7,"numAffected":7,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Decubitus ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Dermatitis psoriasiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG006","numEvents":5,"numAffected":4,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":7,"numAffected":7,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hypertrichosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Photosensitivity reaction","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":6,"numAffected":5,"numAtRisk":38}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG006","numEvents":5,"numAffected":4,"numAtRisk":31},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG008","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":5,"numAffected":4,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":7,"numAffected":6,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":3,"numAffected":3,"numAtRisk":19},{"groupId":"EG018","numEvents":7,"numAffected":6,"numAtRisk":24},{"groupId":"EG019","numEvents":5,"numAffected":4,"numAtRisk":34},{"groupId":"EG020","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG021","numEvents":3,"numAffected":3,"numAtRisk":38}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG006","numEvents":8,"numAffected":5,"numAtRisk":31},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":4,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":5,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":5,"numAffected":5,"numAtRisk":19},{"groupId":"EG018","numEvents":5,"numAffected":5,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG020","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG021","numEvents":5,"numAffected":2,"numAtRisk":38}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":3,"numAffected":2,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Skin hyperpigmentation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":3,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":4,"numAffected":4,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":31},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":5,"numAffected":4,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":3,"numAffected":3,"numAtRisk":38}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":3,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":4,"numAffected":4,"numAtRisk":38}]},{"term":"Otorrhoea","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG016","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Visual acuity reduced","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Visual impairment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":2,"numAffected":2,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":2,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":5,"numAffected":5,"numAtRisk":31},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG008","numEvents":5,"numAffected":5,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":3,"numAffected":3,"numAtRisk":38}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":31},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG008","numEvents":6,"numAffected":6,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":3,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":3,"numAffected":3,"numAtRisk":38}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":21},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":21},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":22},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":22},{"groupId":"EG006","numEvents":6,"numAffected":6,"numAtRisk":31},{"groupId":"EG007","numEvents":5,"numAffected":5,"numAtRisk":38},{"groupId":"EG008","numEvents":16,"numAffected":16,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG014","numEvents":7,"numAffected":5,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":3,"numAffected":3,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":3,"numAffected":3,"numAtRisk":17},{"groupId":"EG021","numEvents":4,"numAffected":4,"numAtRisk":38}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":21},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":21},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":22},{"groupId":"EG003","numEvents":7,"numAffected":5,"numAtRisk":23},{"groupId":"EG004","numEvents":7,"numAffected":5,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG006","numEvents":13,"numAffected":8,"numAtRisk":31},{"groupId":"EG007","numEvents":11,"numAffected":9,"numAtRisk":38},{"groupId":"EG008","numEvents":22,"numAffected":11,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":3,"numAffected":3,"numAtRisk":25},{"groupId":"EG013","numEvents":10,"numAffected":8,"numAtRisk":23},{"groupId":"EG014","numEvents":6,"numAffected":5,"numAtRisk":20},{"groupId":"EG015","numEvents":13,"numAffected":8,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":4,"numAffected":3,"numAtRisk":19},{"groupId":"EG018","numEvents":7,"numAffected":7,"numAtRisk":24},{"groupId":"EG019","numEvents":8,"numAffected":6,"numAtRisk":34},{"groupId":"EG020","numEvents":3,"numAffected":3,"numAtRisk":17},{"groupId":"EG021","numEvents":15,"numAffected":8,"numAtRisk":38}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":3,"numAffected":3,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":3,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":2,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":4,"numAffected":4,"numAtRisk":38}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":4,"numAffected":4,"numAtRisk":38}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":21},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":21},{"groupId":"EG002","numEvents":14,"numAffected":10,"numAtRisk":22},{"groupId":"EG003","numEvents":18,"numAffected":16,"numAtRisk":23},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":42,"numAffected":19,"numAtRisk":31},{"groupId":"EG007","numEvents":25,"numAffected":19,"numAtRisk":38},{"groupId":"EG008","numEvents":40,"numAffected":34,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":4,"numAffected":4,"numAtRisk":25},{"groupId":"EG013","numEvents":28,"numAffected":18,"numAtRisk":23},{"groupId":"EG014","numEvents":17,"numAffected":12,"numAtRisk":20},{"groupId":"EG015","numEvents":5,"numAffected":4,"numAtRisk":22},{"groupId":"EG016","numEvents":11,"numAffected":10,"numAtRisk":15},{"groupId":"EG017","numEvents":6,"numAffected":5,"numAtRisk":19},{"groupId":"EG018","numEvents":14,"numAffected":10,"numAtRisk":24},{"groupId":"EG019","numEvents":24,"numAffected":14,"numAtRisk":34},{"groupId":"EG020","numEvents":10,"numAffected":6,"numAtRisk":17},{"groupId":"EG021","numEvents":33,"numAffected":22,"numAtRisk":38}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":2,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":21},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":21},{"groupId":"EG002","numEvents":12,"numAffected":7,"numAtRisk":22},{"groupId":"EG003","numEvents":11,"numAffected":8,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG006","numEvents":12,"numAffected":10,"numAtRisk":31},{"groupId":"EG007","numEvents":13,"numAffected":11,"numAtRisk":38},{"groupId":"EG008","numEvents":28,"numAffected":15,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":18,"numAffected":8,"numAtRisk":23},{"groupId":"EG014","numEvents":13,"numAffected":9,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":4,"numAffected":4,"numAtRisk":15},{"groupId":"EG017","numEvents":6,"numAffected":5,"numAtRisk":19},{"groupId":"EG018","numEvents":8,"numAffected":6,"numAtRisk":24},{"groupId":"EG019","numEvents":13,"numAffected":9,"numAtRisk":34},{"groupId":"EG020","numEvents":6,"numAffected":5,"numAtRisk":17},{"groupId":"EG021","numEvents":18,"numAffected":12,"numAtRisk":38}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":21},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":8,"numAffected":7,"numAtRisk":31},{"groupId":"EG007","numEvents":6,"numAffected":6,"numAtRisk":38},{"groupId":"EG008","numEvents":11,"numAffected":11,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":4,"numAffected":4,"numAtRisk":15},{"groupId":"EG017","numEvents":5,"numAffected":5,"numAtRisk":19},{"groupId":"EG018","numEvents":4,"numAffected":4,"numAtRisk":24},{"groupId":"EG019","numEvents":6,"numAffected":5,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":10,"numAffected":10,"numAtRisk":38}]},{"term":"Catheter site rash","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":21},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":21},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":22},{"groupId":"EG003","numEvents":11,"numAffected":9,"numAtRisk":23},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":23},{"groupId":"EG005","numEvents":8,"numAffected":6,"numAtRisk":22},{"groupId":"EG006","numEvents":10,"numAffected":8,"numAtRisk":31},{"groupId":"EG007","numEvents":7,"numAffected":6,"numAtRisk":38},{"groupId":"EG008","numEvents":37,"numAffected":16,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG011","numEvents":3,"numAffected":3,"numAtRisk":9},{"groupId":"EG012","numEvents":9,"numAffected":8,"numAtRisk":25},{"groupId":"EG013","numEvents":11,"numAffected":8,"numAtRisk":23},{"groupId":"EG014","numEvents":11,"numAffected":9,"numAtRisk":20},{"groupId":"EG015","numEvents":12,"numAffected":10,"numAtRisk":22},{"groupId":"EG016","numEvents":7,"numAffected":6,"numAtRisk":15},{"groupId":"EG017","numEvents":4,"numAffected":4,"numAtRisk":19},{"groupId":"EG018","numEvents":9,"numAffected":9,"numAtRisk":24},{"groupId":"EG019","numEvents":2,"numAffected":2,"numAtRisk":34},{"groupId":"EG020","numEvents":3,"numAffected":3,"numAtRisk":17},{"groupId":"EG021","numEvents":22,"numAffected":16,"numAtRisk":38}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":3,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":22},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":4,"numAffected":3,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":4,"numAffected":3,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":3,"numAffected":3,"numAtRisk":38}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG021","numEvents":1,"numAffected":1,"numAtRisk":38}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":22},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":22},{"groupId":"EG006","numEvents":6,"numAffected":4,"numAtRisk":31},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":38},{"groupId":"EG008","numEvents":5,"numAffected":5,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":3,"numAffected":2,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":12,"numAffected":8,"numAtRisk":38}]},{"term":"Hepatic cytolysis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":3,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Hypertransaminasaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Contrast media allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Contrast media reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":21},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":2,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":3,"numAffected":2,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":38},{"groupId":"EG008","numEvents":4,"numAffected":3,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":23},{"groupId":"EG014","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":4,"numAffected":4,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG019","numEvents":1,"numAffected":1,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":22},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":2,"numAffected":1,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":3,"numAffected":2,"numAtRisk":15},{"groupId":"EG017","numEvents":5,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":2,"numAffected":2,"numAtRisk":38}]},{"term":"Coronavirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Fungal foot infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Genital herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":19},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]},{"term":"Gingivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":21},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":38},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":23},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":22},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":19},{"groupId":"EG018","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG019","numEvents":0,"numAffected":0,"numAtRisk":34},{"groupId":"EG020","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG021","numEvents":0,"numAffected":0,"numAtRisk":38}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Module 4 was prematurely discontinued by the sponsor for strategic reasons."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"AstraZeneca has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript; it being understood that results shall be published regardless of outcome."},"pointOfContact":{"title":"Global Clinical Lead","organization":"AstraZeneca Clinical Study Information Center","email":"information.center@astrazeneca.com","phone":"+1-877-240-9479"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2024-10-09","uploadDate":"2025-08-27T04:55","filename":"Prot_000.pdf","size":12804824},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2024-02-15","uploadDate":"2025-08-27T04:55","filename":"SAP_001.pdf","size":22711280}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2025-09-17","type":"ESTIMATED"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000613593","term":"durvalumab"},{"id":"C000610954","term":"danvatirsen"},{"id":"C000611951","term":"ceralasertib"},{"id":"C585537","term":"vistusertib"},{"id":"C531550","term":"olaparib"},{"id":"C000614160","term":"trastuzumab deruxtecan"},{"id":"C500926","term":"cediranib"}]}},"hasResults":true}